StockNews.com Begins Coverage on DBV Technologies (NASDAQ:DBVT)

StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT - Free Report) in a report issued on Monday morning. The brokerage issued a hold rating on the stock.

DBVT has been the subject of several other research reports. HC Wainwright reissued a "buy" rating and issued a $5.00 target price on shares of DBV Technologies in a research note on Thursday, August 1st. JMP Securities reissued a "market outperform" rating and issued a $5.00 target price on shares of DBV Technologies in a research note on Tuesday, September 24th.

DBV Technologies Stock Performance

Shares of NASDAQ:DBVT remained flat at $0.70 during midday trading on Monday. The stock had a trading volume of 27,310 shares, compared to its average volume of 51,939. The company has a market capitalization of $67.64 million, a PE ratio of -0.84 and a beta of 0.67. DBV Technologies has a fifty-two week low of $0.50 and a fifty-two week high of $2.28. The firm has a fifty day simple moving average of $0.79 and a 200 day simple moving average of $0.97.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last released its quarterly earnings results on Tuesday, July 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.08). The firm had revenue of $1.16 million for the quarter, compared to analyst estimates of $1.42 million. DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. During the same period last year, the firm earned ($0.26) EPS. As a group, sell-side analysts anticipate that DBV Technologies will post -1.43 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in DBV Technologies stock. Yiheng Capital Management L.P. raised its holdings in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) by 6.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,568,909 shares of the company's stock after buying an additional 327,345 shares during the quarter. DBV Technologies makes up approximately 0.2% of Yiheng Capital Management L.P.'s holdings, making the stock its 15th largest holding. Yiheng Capital Management L.P. owned 2.89% of DBV Technologies worth $4,172,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 71.74% of the company's stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.